Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Shares of Danish biotech Ascendis Pharma leapt, despite the company revealing that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the TransCon PTH (palopegteriparatide) New Drug Application (NDA) for the treatment of adults with hypoparathyroidism. 2 May 2023
Maze Therapeutics, a privately-held Californian company translating genetic insights into new precision medicines, has announced the signing of an exclusive worldwide license agreement with French pharma major Sanofi. 2 May 2023
Shares of New Jersey, USA-based biotech firm Iveric Bio closed up nearly 16% at $38.05 yesterday, on the news of an agreed takeover bid from Japanese pharma major Astellas Pharma, with the latter rising 2.2% to 2,093 yen. 2 May 2023
USA-based Nanoscope Therapeutics, a biotech developing gene therapies for retinal degenerative diseases, has presented results from the Phase IIb RESTORE trial of MCO-010 for the treatment of retinitis pigmentosa at the ARVO Annual Meeting. 2 May 2023
A 12% jump in the stock price of Avadel Pharmaceuticals on Monday reflects market confidence in the firm’s newly-approved cataplexy med Lumryz (sodium oxybate). 2 May 2023
As a next step in focusing on the US market, the board of Swedish diagnostic testing and precision medicines firm Immunovia AB has decided to appoint Jeff Borcherding, until now president of Immunovia’s US operation, as global chief executive 2 May 2023
Nektar Therapeutics has announced that it will be regaining the full rights to rezpegaldesleukin (REZPEG; NKTR-358) from Eli Lilly (NYSE: LLY) which concludes the two companies’ collaboration that begun in 2017. 28 April 2023
Cambridge, USA-based Orbital Therapeutics, which debuted last September with the vision of enhancing global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible, has now announced the successful closing of a $270 million Series A financing. 27 April 2023
UK-based company Epsilogen is even more confident in its claim to be a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer following three new senior hires. 26 April 2023
Shares of Morphic Therapeutics experienced volatility yesterday, after the US biotech reported positive top-line data from the main cohort of the open-label EMERALD-1 Phase IIa study of MORF-057, an oral small molecule inhibitor of the α4β7 integrin, in adults with moderate to severe ulcerative colitis (UC). 26 April 2023
Kidney disease specialist Akebia Therapeutics saw its shares lifted over 6% on Monday, following a European approval for Vafseo (vadadustat). 26 April 2023
It has been a challenging first quarter for biotech financing, but a company founded by British clinical-stage biopharma firm PureTech Health has secured over $100 million for its work on the microbiome. 25 April 2023
Idorsia’s shares were down more than 9% at 8.76 Swiss francs by early afternoon, as the Switzerland-based biotech announced its financial results for the first quarter of 2023. 25 April 2023
Californian specialty drugmaker Amphastar Pharmaceuticals has bought Baqsimi (glucagon) from Eli Lilly, in a deal worth over a billion dollars. 25 April 2023
Detailed results have been presented from the NEURO-TTRansform Phase III trial in hereditary transthyretin-mediated amyloid polyneuropathy testing AstraZeneca and Ionis’ eplontersen. 25 April 2023
UK-based drugmaker Advanz Pharma has bought global rights to the testosterone gel Tostran (testosterone) from Japanese biotech Kyowa Kirin. 25 April 2023
Foghorn Therapeutics’ shares slid as much as 21% in pre-market activity on Monday, and closed down 7.9% at $6.19, after the US cancer-focused biotech announced a setback on the FHD-609 program in synovial sarcoma and SMARCB1-deleted tumors. 25 April 2023
Genetic Medicines company 4D Molecular Therapeutics is to acquire Aevitas’ proprietary rights to its short-form human complement factor H (sCFH) asset for the treatment of complement-mediated diseases. 24 April 2023
USA-based company ImmunoGen, a specialist in the field of antibody-drug conjugates (ADCs) for the treatment of cancer, has appointed Isabel Kalofonos as senior vice president and chief commercial officer. 24 April 2023
US retinal disease specialist Apellis Pharmaceuticals has announced post hoc analyses from the 24-month, Phase III OAKS and DERBY studies evaluating Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). 24 April 2023